文献速递母胎医学产科

胎儿积液谱系背后的遗传疾病

Genetic diseases underlying a spectrum of fetal effusions.
PubMed 文献 · Am J Obstet Gynecol · 2025-05-08

美国前瞻性队列研究纳入118例非免疫性胎儿水肿及其他胎儿积液妊娠,外显子测序诊断阳性率为23%(27/118)。合并结构异常时,颈项透明层增厚或囊性水瘤的诊断率显著高于无结构异常者(42% vs 0%,P<.01)。非免疫性胎儿水肿和单个积液的诊断率在有无结构异常间无显著差异。

要点

  • 非免疫性胎儿水肿及其他胎儿积液的外显子测序诊断阳性率为23%(27/118)。
  • 颈项透明层增厚或囊性水瘤合并结构异常时诊断率42%,无结构异常时0%(P<.01)。
  • 非免疫性胎儿水肿和单个积液的诊断率在有无结构异常间无显著差异。

核心结论

  • 外显子测序在各类胎儿积液中诊断率均高,但孤立性颈项透明层增厚或囊性水瘤除外。
  • 观察到遗传疾病在宫内表现为胎儿积液的多种模式,为咨询和管理提供信息。

研究设计与样本

  • 前瞻性队列研究,纳入美国各地非免疫性胎儿水肿及其他胎儿积液妊娠。
  • 纳入标准为染色体微阵列和/或核型结果非诊断性且存在至少一种胎儿积液,包括颈项透明层≥3.5 mm、囊性水瘤、胸腔积液、心包积液、腹水和/或皮肤水肿。
  • 外显子测序由本机构临床实验室改进修正案认证实验室完成,共118例妊娠接受测序。
  • 主要结局为按胎儿积液类型及是否合并结构异常的外显子测序诊断率。

主要发现

  • 总体诊断阳性率为23%(27/118)。
  • 非免疫性胎儿水肿合并结构异常诊断率为21%(9/42),无结构异常为40%(6/15),P=.15。
  • 单个积液如胸腔积液合并结构异常诊断率为23%(6/26),无结构异常为17%(1/6),P=.61。
  • 颈项透明层增厚或囊性水瘤合并结构异常诊断率为42%(5/12),无结构异常为0%(0/17),P<.01。
  • RASopathies和肌肉骨骼疾病可表现为所有类型积液,而出生后神经发育迟缓的疾病表现为除非免疫性胎儿水肿外的所有类型积液。

临床怎么用

  • 研究结果可为胎儿积液的咨询和临床管理提供重要信息。
  • 研究结果强调外显子测序在非免疫性胎儿水肿之外的胎儿积液中的效用。
  • 研究结果有助于为表型驱动检测如外显子测序提供准确结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Nonimmune hydrops fetalis is well understood to be heterogenous and the common endpoint of many genetic diseases. However, less is known about the prevalence and presenting features of genetic diseases that underlie other types of fetal effusions such as single effusions, leaving uncertainty in clinical practice about optimal approaches to testing and counseling for these pregnancies. We aimed to determine the diagnostic yield of exome sequencing by type of fetal effusion and presence of concurrent structural abnormalities and to identify the unique presenting features of underlying genetic diseases. STUDY DESIGN: We conducted a prospective cohort study of pregnancies with nonimmune hydrops fetalis and other fetal effusions, with participants enrolled from across the United States. Inclusion criteria were nondiagnostic results of chromosomal microarray and/or karyotype and the presence of at least 1 fetal effusion, including nuchal translucency ≥3.5 mm, cystic hygroma, pleural effusion, pericardial effusion, ascites, and/or skin edema. Exome sequencing was performed by our institution's Clinical Laboratory Improvement Amendments-approved laboratory and results were returned to participants and their providers. Detailed fetal phenotypic data were ascertained and used to inform genetic variant interpretation, including fetal imaging findings (ultrasound, magnetic resonance imaging, and echocardiogram), pathology reports, and laboratory reports. Pregnancies with a variant or variants classified as pathogenic or likely pathogenic were considered diagnostic or positive. The primary outcome was the diagnostic yield of exome sequencing by the type of fetal effusion, with and without concurrent structural abnormalities. Secondary outcomes were the types of fetal effusions observed by category of genetic disease. RESULTS: In all, 118 pregnancies with nonimmune hydrops fetalis and other effusions underwent exome sequencing and 23% (27/118) had positive (diagnostic) findings. Pregnancies with nonimmune hydrops fetalis with and without concurrent structural abnormalities had diagnostic yields of 21% (9/42) and 40% (6/15), respectively (P=.15). Single effusions such as pleural effusion with and without concurrent structural abnormalities had diagnostic yields of 23% (6/26) and 17% (1/6), respectively (P=.61). The diagnostic yield for increased nuchal translucency or cystic hygroma was significantly greater for pregnancies with concurrent structural abnormalities (42%, 5/12) compared to those without (0%, 0/17, P<.01). We further observed numerous patterns in terms of how genetic diseases present in utero, such as RASopathies and musculoskeletal disorders demonstrating all types of effusions, while other disorders marked by neurodevelopmental delays after birth demonstrated all types of effusions except for nonimmune hydrops fetalis. CONCLUSION: The diagnostic yield of exome sequencing was high across all types of effusions including single effusions with and without concurrent structural abnormalities, with the exception of isolated increased nuchal translucency or cystic hygroma. Furthermore, we observed numerous patterns in terms of how genetic diseases present in utero with fetal effusions. These findings contribute important information for counseling and clinical management, highlight the utility of exome sequencing for fetal effusions beyond nonimmune hydrops fetalis, and inform accurate results of phenotype-driven tests such as exome sequencing.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gulrajani NB, Lianoglou BR, Tick K, et al. Genetic diseases underlying a spectrum of fetal effusions. Am J Obstet Gynecol. 2025. PMID: 40348118. doi:10.1016/j.ajog.2025.04.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。